Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Leadership Upheaval Could Delay Initiatives Impacting Biopharma

Executive Summary

Secretary Price will be succeeded on an acting basis by HHS acting assistant secretary for health Donald Wright, and everything from development of the executive order on drug pricing to pending Medicare reimbursement experiments could see a pause as part of the transition.

You may also be interested in...



With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives

Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.

Groundhog Day For HHS And Drug Pricing? Why It Might Be Different This Time

President Trump has directed his new HHS Secretary to bring down drug prices – starting 2018 exactly the same way as 2017. But this time it could end differently.

OMB's Grogan Talks Drug Pricing And Taking On 'Sacred Cows'

Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.

Related Content

Topics

UsernamePublicRestriction

Register

PS121675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel